Skip to main content

Multiple Sclerosis Spasticity and cannabis in Montana

The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.

Listed qualifying condition
✓ Yes
LEGAL
1 oz usable cannabis un…
POSSESSION
$5/yr
STATE FEE
5–14 d
TIMELINE
Listed qualifying condition. The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.

Montana statute and program

The Montana Medical Marijuana Program is the operating authority for Montana patient certification. The authoritative legal text is: Montana Code Annotated Title 16 Chapter 12: Marijuana Regulation and Taxation Act. The program portal is at Montana Medical Marijuana Program.

What the evidence says about cannabis and Multiple Sclerosis Spasticity

The 2017 NASEM consensus report found substantial evidence that oral cannabinoids improve patient-reported spasticity symptoms in adults with MS. Clinician-rated outcomes show smaller effects than patient-reported outcomes, suggesting a meaningful subjective benefit even where objective measures change less.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Multiple Sclerosis Spasticity page.

How to qualify in Montana

The Montana Medical Marijuana Program requires the following registration steps for a Multiple Sclerosis Spasticity patient (or any qualifying diagnosis):

  1. Get certified by a Montana-licensed physician. Under Mont. Code Ann. §50-46-301 et seq. (Montana Marijuana Regulation and Taxation Act, voters approved 2004 and modernized 2021), any Montana-licensed MD, DO, advanced practice registered nurse, or physician assistant authorized to prescribe controlled substances may certify a patient. Qualifying debilitating medical conditions include cancer, glaucoma, HIV/AIDS, MS, epilepsy, intractable nausea, severe chronic pain, cachexia, severe muscle spasms, PTSD, Crohn’s, central nervous system disorders, painful peripheral neuropathy, and admittance to hospice care.
  2. Apply through the Montana DPHHS portal. The patient creates an account in the Montana Department of Public Health and Human Services (DPHHS) Cannabis Control Division registry portal, uploads the physician certification, a Montana driver license or state ID, and a passport-style photograph. Caregivers (called "providers" under Montana law) register separately and pass a state background check.
  3. Pay the $5 state registration fee. The annual Montana medical marijuana registry card fee is $5 — among the lowest in the United States. Patients pay only this nominal state fee plus the physician certification fee. Caregivers pay a separate higher provider licensing fee through the Cannabis Control Division.
  4. Receive the card and purchase from a Montana dispensary. Montana medical marijuana registry cards are typically issued within 5 to 10 business days of complete application. Patients may purchase up to 5 ounces of usable cannabis per month from any of the licensed Montana medical dispensaries and may cultivate up to 4 mature plus 4 seedling plants. Adult-use retail launched January 1, 2022 under HB 701 (2021); medical patients retain the lower 4% medical tax versus the 20% adult-use rate and access to higher-potency products.
State registration fee
$5
Physician visit (typical)
$150–$300
Certification to card
5–14 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Montana registration steps, fees, and reciprocity rules, see the Montana cannabis-laws page.

ICD-10 code

A certifying physician documenting Multiple Sclerosis Spasticity for the Montana medical cannabis program will typically record ICD-10 G35 or SNOMED-CT 24700007 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Montana list Multiple Sclerosis Spasticity as a qualifying condition for medical cannabis?

Yes. Montana explicitly lists Multiple Sclerosis Spasticity as a qualifying condition under Montana Medical Marijuana Program. A patient with a documented Multiple Sclerosis Spasticity diagnosis can pursue state-program certification with a physician registered in the state. The qualifying-condition list is published by the state at https://dphhs.mt.gov/marijuana and may change as regulators add, remove, or refine entries. Inclusion on the list does not guarantee certification — a physician still has to evaluate the patient and decide that medical cannabis is appropriate for that specific case under Montana rules.

How do I get a Montana medical marijuana card for Multiple Sclerosis Spasticity?

Step one is finding a physician licensed in Montana who is registered with Montana Medical Marijuana Program and willing to evaluate Multiple Sclerosis Spasticity cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Montana does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. The authoritative source for the current process is the Montana Medical Marijuana Program site at https://dphhs.mt.gov/marijuana; the state updates fees, forms, and physician registration rules periodically.

What does the evidence say about cannabis for Multiple Sclerosis Spasticity?

For Multiple Sclerosis Spasticity, evidence is described as strong (e.g. multiple randomized controlled trials or systematic reviews supporting effect). The mmjnow condition page for Multiple Sclerosis Spasticity lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Multiple Sclerosis Spasticity should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Multiple Sclerosis Spasticity and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Multiple Sclerosis Spasticity; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. Montana Code Annotated Title 16 Chapter 12: Marijuana Regulation and Taxation Actaccessed May 16, 2026
  2. Montana Department of Revenue: Cannabis Control Divisionaccessed May 16, 2026
  3. Montana Department of Public Health and Human Services: Medical Marijuana Programaccessed May 16, 2026
  4. Wikipedia: Cannabis in Montanaaccessed May 16, 2026
  5. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 14, 2026

    “Substantial evidence that oral cannabinoids are effective for improving patient-reported MS spasticity symptoms.”

  6. National MS Society: Marijuanaaccessed May 14, 2026